However, DIO-MASH FGF15INT-KO mice showed a specific pathology involving the development of microvesicular hepatic steatosis and increased circulating FGF21 levels that should be further evaluated in the development of metabolic liver disease. Here, FGF21 is linked to Hepatic steatosis.